Add to ORKGIntroduction: HSCT is a curative option for many patients (pts) with hematological malignancies. Significant advances in supportive care and conditioning regimens over the past decade have allowed the extension of this therapy to older individuals. Information regarding the outcomes of this older subset of pts undergoing HSCT is limited, especially those undergoing haploidential (HI) HSCT. Objectives: To describe the outcomes of patients 60 years of age or older undergoing haploidential and matched related (MR) HSCT using the 2-step approach
Hematopoietic stem cell transplant (HSCT) is the preferred treatment for young patients with multipl...
AbstractAs older patients are eligible for allogeneic hematopoietic cell transplantation (HCT), olde...
Long-term survival rates for older patients with newly diagnosed acute myeloid leukemia (AML) are ex...
AbstractAllogeneic hematopoietic stem cell transplantation (HSCT) can achieve durable remissions in ...
Reduced-intensity-conditioning (RIC) hematopoietic stem cell transplantation (HSCT) is markedly unde...
AbstractHaploidentical hematopoietic stem cell transplantation (HSCT) is an attractive alternative d...
AbstractTo compare the clinical outcomes of older (age ≥55 years) non-Hodgkin lymphoma (NHL) patient...
AbstractAllogeneic hematopoietic stem cell transplantation (HSCT) can achieve durable remissions in ...
Context A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell t...
AbstractNon-Hodgkin lymphoma (NHL) disproportionately affects older patients, who do not often under...
In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell transplantation (HC...
In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell transplantation (HC...
View full abstracthttps://openworks.mdanderson.org/leading-edge/1007/thumbnail.jp
Reduced-intensity-conditioning (RIC) hematopoietic stem cell transplantation (HSCT) is markedly unde...
Hematopoietic stem cell transplant (HSCT) is the preferred treatment for young patients with multipl...
Hematopoietic stem cell transplant (HSCT) is the preferred treatment for young patients with multipl...
AbstractAs older patients are eligible for allogeneic hematopoietic cell transplantation (HCT), olde...
Long-term survival rates for older patients with newly diagnosed acute myeloid leukemia (AML) are ex...
AbstractAllogeneic hematopoietic stem cell transplantation (HSCT) can achieve durable remissions in ...
Reduced-intensity-conditioning (RIC) hematopoietic stem cell transplantation (HSCT) is markedly unde...
AbstractHaploidentical hematopoietic stem cell transplantation (HSCT) is an attractive alternative d...
AbstractTo compare the clinical outcomes of older (age ≥55 years) non-Hodgkin lymphoma (NHL) patient...
AbstractAllogeneic hematopoietic stem cell transplantation (HSCT) can achieve durable remissions in ...
Context A minimally toxic nonmyeloablative regimen was developed for allogeneic hematopoietic cell t...
AbstractNon-Hodgkin lymphoma (NHL) disproportionately affects older patients, who do not often under...
In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell transplantation (HC...
In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell transplantation (HC...
View full abstracthttps://openworks.mdanderson.org/leading-edge/1007/thumbnail.jp
Reduced-intensity-conditioning (RIC) hematopoietic stem cell transplantation (HSCT) is markedly unde...
Hematopoietic stem cell transplant (HSCT) is the preferred treatment for young patients with multipl...
Hematopoietic stem cell transplant (HSCT) is the preferred treatment for young patients with multipl...
AbstractAs older patients are eligible for allogeneic hematopoietic cell transplantation (HCT), olde...
Long-term survival rates for older patients with newly diagnosed acute myeloid leukemia (AML) are ex...